Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Mycobacterium tuberculosis coenzyme A biosynthesis enzymes constitute a vital metabolic pathway essential for the survival, persistence, and virulence of the tuberculosis-causing bacterium [1]. Coenzyme A (CoA) is a universal cofactor required for approximately 9% of all cellular enzymatic reactions, including the tricarboxylic acid cycle, fatty acid metabolism, and the synthesis of complex cell wall lipids like mycolic acids [1, 3]. In M. tuberculosis, this pathway involves several key enzymes: pantothenate kinase (PanK/CoaA), the bifunctional phosphopantothenoylcysteine synthetase/decarboxylase (CoaBC), phosphopantetheine adenylyltransferase (CoaD), and dephospho-CoA kinase (CoaE) [2, 3]. These enzymes are considered high-value therapeutic targets because they are essential for the pathogen and often exhibit significant structural differences from their human orthologs, allowing for selective inhibition [1, 4]. Inhibition of these enzymes leads to the depletion of intracellular CoA pools, which catastrophically disrupts energy production and cell envelope integrity [3, 4]. The first-line antitubercular drug pyrazinamide, via its active form pyrazinoic acid, has been shown to target PanD, an enzyme in the pantothenate/CoA biosynthetic route, thereby validating the pathway's clinical relevance [1, 4]. Recent drug discovery efforts have identified potent small-molecule inhibitors, such as compound 1f targeting CoaB, which demonstrate whole-cell activity against M. tuberculosis [3]. Despite the potential, challenges remain regarding the ability of the bacteria to scavenge host-derived intermediates and the development of resistance through metabolic bypass [1, 3].
Inhibition of coenzyme A biosynthesis leading to depletion of essential metabolic cofactors and disruption of lipid and energy metabolism.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Mycobacterium tuberculosis coenzyme A biosynthesis enzymes (Mtb CoA biosynthesis enzymes).